Abstract:
A method for establishing an identity management trust, and an IDentification Provider (IDP) and a Service Provider (SP) are provided in the present disclosure. The method comprises: after receiving an access from a user, an SP determines whether an IDP to which the user attaches is located in a trust domain of the SP (S102); if the IDP to which the user attaches is not located in the trust domain of the SP, the SP inquires of an IDP in a local trust domain about the IDP to which the user attaches (S104); if the SP receives information of the IDP to which the user attaches, wherein the information is returned by an IDP in the local trust domain, the SP adds the IDP to which the user attaches to a temporary trust list to establish a trust for the IDP to which the user attaches (S106). The present disclosure can establish a trust relationship between an SP and any IDP in case of adding or not adding extra devices, ensuring the user to obtain desired services after logging on for one time.
Abstract:
Potent and selective ligands for the dopamine 3 (D3) receptor are disclosed. The D3 receptor ligands have a structural formula: wherein R1 is C1-6 alkyl or C3-6cycloalkyl; or wherein R2 is substituted with one or two halogen(s) or OC1-3alkyl.
Abstract:
The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).
Abstract:
A method for establishing an identity management trust, and an IDentification Provider (IDP) and a Service Provider (SP) are provided in the present disclosure. The method comprises: after receiving an access from a user, an SP determines whether an IDP to which the user attaches is located in a trust domain of the SP (S102); if theIDP to which the user attaches is not located in the trust domain of the SP, the SP inquires of an IDP in a local trust domain about the IDP to which the user attaches (S104); if the SP receives information of the IDP to which the user attaches, wherein the information is returned by an IDP in the local trust domain, the SP adds the IDP to which the user attaches to a temporary trust list to establish a trust for the IDP to which the user attaches (S106). The present disclosure can establish a trust relationship between an SP and any IDP in case of adding or not adding extra devices, ensuring the user to obtain desired services after logging on for one time.
Abstract:
The present invention discloses a digital signature scheme based on braid group conjugacy problem and a verifying method thereof, wherein a signatory S selects three braids xεLBm(l), x′εBn(l), aεBn(l), and considers braid pair (x′,x) as a public key of S, braid a as a private key of S; Signatory S uses hash function h for a message M needing signature to get y=h(M)εBn(l); generating a braid bεRBn−1−m(l) randomly, then signing M with a and b to obtain Sign(M)=a−1byb−1a; a signature verifying party V obtains the public key of S, calculating the message M by employing hash function h, obtaining the y=h(M); judging whether sign(M) and y, sign(M)x′ and xy are conjugate or not, if yes, sign(M) is a legal signature of message M; the present invention reduces the number of braids involved and the number for conjugacy decision without reducing security, thereby improving the operation efficiency of signature.
Abstract:
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Abstract:
The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
Abstract:
Potent and selective ligands for the dopamine 3 (D3) receptor are disclosed. The D3 receptor ligands have a structural formula (I) wherein X is C═O or SO2, R1 is C1-6 alkyl, R2 is aryl, heteroaryl, aryl, —(CH2)1-3aryl, or —(CH2)1-3heteroaryl, and n is 0 or 1. Methods of using the D3 receptor ligands in the treatment of diseases and conditions wherein modulation of the D3 receptor provides a benefit also are disclosed.
Abstract:
Inhibitors of STAT3 are disclosed. Methods of using the STAT3 inhibitors in the treatment of diseases and conditions wherein inhibition of STAT3 provides a benefit, like cancers, also are disclosed.
Abstract:
The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of XIAP family proteins. In particular, the present invention provides embelin and other XIAP inhibitors and methods of using these compounds as antagonists of the anti-apoptotic effects of XIAP family member proteins. The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases).